For many childhood brain tumour survivors, survival means chronic disease.
For CBTS, QoS assessment should include tumour-, treatment- and host-related factors.
Many CBTSs' dilemma: treatment takes CNS tumour, but bates CNS function.
Predictive markers of late effects are needed for individual treatment planning.
Empowering survivors and stakeholders: a new mission in Paediatric Neurooncology.